Takeaways: Roche’s pCPA win for Itovebi is a major reimbursement de-risking event in Canada, because it moves the drug much closer to broad public coverage after a ...
Browsing Tag: PIK3CA inhibitor
Takeaways: Roche’s pCPA win for Itovebi is a major reimbursement de-risking event in Canada, because it moves the drug much closer to broad public coverage after a ...